Innate Immune Cells' Contribution to Systemic Lupus Erythematosus

This study was supported in part by the Projects: Redes Internacionales (REDI170651) (to AH and MI); Proyecto interno Universidad Autónoma de Chile (DIUA 134-2018) and by the Pilot Research Grant (PP-1805-30965) from the National Multiple Sclerosis Society (to AH); Proyecto Genera-Autónoma N°UA 17-04 and FONDECYT de Inicio N° 11160592, CONICYT (to NE) and Proyecto Vicerrectoría de Investigación, Pontificia Universidad Católica de Chile Puente P1802 (to CL). Conflict of Interest Statement The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest. Acknowledgments We acknowledge Dr. Nicole M. Chapman (St. Jude Children's Research Hospital), for critical reading of the manuscript. References 1. Ding C, Foote S, Jones G. B-cell-targeted therapy for systemic lupus erythematosus: an update. BioDrugs. (2008) 22:239–49. doi: 10.2165/00063030-200822040-00003 PubMed Abstract | CrossRef Full Text | Google Scholar 2. Kalunian K, Merrill JT. New directions in the treatment of systemic lupus erythematosus. Curr Med Res Opin. (2009) 25:1501–14. doi: 10.1185/03007990902929104 PubMed Abstract | CrossRef Full Text | Google Scholar 3. Crispín JC, Liossis SN, Kis-Toth K, Lieberman LA, Kyttaris VC, Juang YT et al. Tsokos: pathogenesis of human systemic lupus erythematosus: recent ...
Source: Frontiers in Immunology - Category: Allergy & Immunology Source Type: research